ELOX (Eloxx Pharmaceuticals) EPS without NRI: $-6.58 (TTM As of Dec. 2025)


ELOX Eloxx Pharmaceuticals Inc ELOX
17 GF Score
Price $11.49
! 1 Warning Sign
View Full Analysis

What is Eloxx Pharmaceuticals EPS without NRI?

Eloxx Pharmaceuticals ELOX -8.00% 17 EPS without NRI is $-6.58 as of Dec. 2025. GuruFocus rates ELOX with a GF Score™ of 17/100. The stock has 1 warning sign investors should review. Among 1,166 Biotechnology companies, Eloxx Pharmaceuticals ranks better than 91.6% on this metric.

Eloxx Pharmaceuticals's earnings per share without non-recurring items for the six months ended in Dec. 2025 was $-6.58. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.58.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Eloxx Pharmaceuticals's EPS without NRI or its related term are showing as below:

ELOX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -549.4   Med: 28.2   Max: 70.9
Current: 67

ELOX's 3-Year EPS without NRI Growth Rate is ranked better than
91.6% of 1166 companies
in the Biotechnology industry
Industry Median: 16.65 vs ELOX: 67.00

Eloxx Pharmaceuticals's EPS (Diluted) for the six months ended in Dec. 2025 was $-5.39. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-5.39.

Eloxx Pharmaceuticals's EPS (Basic) for the six months ended in Dec. 2025 was $-5.39. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $-5.39.


Eloxx Pharmaceuticals  (NAS:ELOX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Eloxx Pharmaceuticals EPS without NRI Related Terms


Eloxx Pharmaceuticals EPS without NRI Historical Data

* Premium members only.

The historical data trend for Eloxx Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eloxx Pharmaceuticals EPS without NRI Chart

Eloxx Pharmaceuticals Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -423.06 -182.91 -78.90 -10.38 -6.58

Eloxx Pharmaceuticals Semi-Annual Data
Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -423.06 -182.91 -78.90 -10.38 -6.58

ELOX vs ESLA, RNXT, ABVC: EPS without NRI Comparison

For the Biotechnology subindustry, Eloxx Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eloxx Pharmaceuticals PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eloxx Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Eloxx Pharmaceuticals's PE Ratio without NRI falls into.


ELOX
17GF Score
Eloxx Pharmaceuticals Inc ELOX
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eloxx Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $-6.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-6.58 mean?
Eloxx Pharmaceuticals (ELOX) has a EPS without NRI of $-6.58 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Eloxx Pharmaceuticals and its competitors. According to the industry distribution chart, Eloxx Pharmaceuticals ranks #98 out of 1166 companies in the Biotechnology industry, placing it in the top 8.4%.
Is Eloxx Pharmaceuticals' EPS without NRI too high?
Eloxx Pharmaceuticals' current EPS without NRI is $-6.58. Based on the distribution chart, Eloxx Pharmaceuticals ranks #98 out of 1166 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Eloxx Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Eloxx Pharmaceuticals' EPS without NRI compare to ESLA and RNXT?
According to the Biotechnology industry distribution chart, Eloxx Pharmaceuticals ranks #98 out of 1166 companies for EPS without NRI. This places Eloxx Pharmaceuticals in the top 8% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.65, based on 1,166 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Eloxx Pharmaceuticals and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eloxx Pharmaceuticals's current EPS without NRI is $-6.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eloxx Pharmaceuticals stock overvalued right now?
Eloxx Pharmaceuticals (ELOX) has a current EPS without NRI of $-6.58. The current EPS without NRI is $-6.58. Eloxx Pharmaceuticals' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Eloxx Pharmaceuticals (ELOX), the current EPS without NRI is $-6.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eloxx Pharmaceuticals Business Description

Address 10 Court Street, P.O. Box 274, Arlington, MA, USA, 02476
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
17GF Score

Get the complete analysis for ELOX

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.49
Price